Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083278
Status:
COMPLETED
Last Update Posted:
2012-04-27
First Post:
2004-05-17
Brief Title:
Study of MDX-010 in Stage IV Breast Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase II Study of MDX-010 in Patients With Stage IV Adenocarcinoma of the Breast
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase II study is designed to treat patients who have been diagnosed with Stage IV Breast Cancer which has progressed despite treatment with primary therapies including hormonal therapy chemotherapy and antibody therapy Thirty-three patients will be treated with the monoclonal antibody MDX-010 The initial antitumor activity profile of MDX-010 will be determined as well as identification of the induction of any antitumor immunity following the MDX-010 treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CA184-015 | OTHER | BMS | None |